UCB Deal History & Licensing Activity
UCB is a large pharma headquartered in Belgium. Over the past three years, UCB has been involved in 2 licensing and acquisition transactions, with a primary focus on Cell Therapy (4 deals). The company currently has 50 active clinical trials, primarily in CNS Disorders.
Deals (12mo)
5
Active Trials
50
Top Modality
Cell Therapy
Focus Area
CNS Disorders
UCB Recent Deal Activity
Licensing, acquisition, and partnership transactions involving UCB in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| NRTX-1001 | Neurona Therapeutics | Cell Therapy | Phase 1 | acquisition | Apr 17, 2026 |
| Neurona epilepsy portfolio | Neurona Therapeutics | Cell Therapy | Unknown | acquisition | Apr 15, 2026 |
UCB Pipeline Focus
Therapeutic areas and modalities where UCB is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
UCB Strategic Signals
Key indicators of UCB's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
UCB Clinical Pipeline
UCB has 50 active clinical trials across 6 development phases.
3
Not Applicable
9
Unknown
1
Phase 4
6
Phase 1
5
Phase 2
26
Phase 3
See How Your Asset Matches UCB's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for CNS Disorders assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Neurology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for neurology
Cell Therapy Benchmarks
Upfront, milestone, and royalty benchmarks for cell therapy deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About UCB Licensing & Deal Activity
UCB is a large pharma company based in Belgium that has been actively engaged in licensing transactions across the biopharma landscape. With 2 deals over the past three years, UCB ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for UCB include CNS Disorders (21 deals and trials), Autoimmune (14 deals and trials), Neurology (2 deals and trials), and Mega Deals (2 deals and trials). In terms of modality, UCB has shown particular interest in cell therapy.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for UCB and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against UCB's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.